Zonisamide: Sulfonamide Anticonvulsant
Zonisamide is a 1,2-benzisoxazole sulfonamide derivative with a broad spectrum of anticonvulsant mechanisms. It blocks voltage-dependent sodium channels and T-type calcium channels, reduces sustained repetitive neuronal firing, and has weak carbonic anhydrase inhibitory activity. This multi-mechanism profile contributes to its efficacy across multiple seizure types.
Product Profile
| CAS Number | 68291-97-4 |
|---|---|
| Molecular Formula | C8H8N2O3S |
| Appearance | White to off-white crystalline powder |
| Therapeutic Category | Anticonvulsant |
| Storage | Room temperature |
Applications
Zonisamide is approved as adjunctive therapy for partial-onset seizures in adults with epilepsy. In Japan, where it was first marketed, it is also approved for generalized seizures. Its long half-life (approximately 63 hours) permits once-daily dosing, with typical maintenance doses of 200–400 mg/day. Zonisamide is associated with weight loss, which can be advantageous or problematic depending on the patient. In veterinary neurology, zonisamide is used as an add-on anticonvulsant in dogs with refractory epilepsy, typically at 5–10 mg/kg twice daily, and is preferred in dogs with hepatic concerns where phenobarbital is contraindicated.
Why Source from TCS
TCS supplies zonisamide to pharmaceutical companies across Europe and globally. Flexible order quantities from development samples to commercial volumes. Contact us with your target market and project requirements for a tailored quotation.
FAQ
What information should be included in an inquiry for Zonisamide 68291-97-4?
A useful inquiry normally includes the product name, target application, estimated quantity, destination market, and any specific documentation or packaging requests.
How is Zonisamide 68291-97-4 usually evaluated for sourcing?
This product is positioned for pharmaceutical sourcing discussions covering development, pilot, or commercial demand, subject to the buyer confirming application scope, market, and document requirements.
What documentation and commercial points are commonly reviewed before buying Zonisamide 68291-97-4?
For pharmaceutical API procurement, buyers commonly align on specification review, target market, batch or annual demand, packaging expectations, and the documentation package needed for the project.
Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.